Postmenopausal exogenous hormone therapy and Melanoma risk in women : A systematic review and time-response meta-analysis
Copyright © 2020 Elsevier Ltd. All rights reserved..
A favourable option to management symptoms during menopausal transition is menopausal hormone therapy (MHT) but relation among MHT and risk of melanoma is controversial. This study aims to identify, analyse and present the evidence surrounding post-menopausal exogenous hormone therapy and the risk for melanoma in women. A systematic searches of database was conducted in PubMed/MEDLINE, Scopus, and Cochrane without time, region, and language restrictions from inception to April 2020. The DerSimonian and Laird random-effects model was used to estimate combined risk ratio (RR) and 95% confidence intervals (CI). Subgroup analysis and time-response analysis was conducted based on the formulation of used hormone and length of hormone therapy. Combined results from fourteen studies that containing 19 arms with 1,164,077 participants which 4273 of them had melanoma cancer showed increase risk of melanoma in the hormone-treated versus control group 1.14 (95% CI 1.05-1.24, I2: 21%). The stronger and significant relationship between MHT and risk of melanoma was in participants who used oestrogen formulation (RR 1.32, 95% CI 1.17-1.49, I2 = 0%). Moreover, a significant non-linear time-response relation between MHT and melanoma was also in initial three years of MHT (Coef1 = 0.2423, p1 < 0.01). This study reveals a significant direct relationship between the MHT and risk of melanoma in postmenopausal women.
| Errataetall: |
CommentIn: Pharmacol Res. 2022 Feb;176:106054. - PMID 34979234 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:160 |
|---|---|
| Enthalten in: |
Pharmacological research - 160(2020) vom: 02. Okt., Seite 105182 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Tang, Xiaoling [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Hormone therapy |
|---|
| Anmerkungen: |
Date Completed 13.08.2021 Date Revised 22.03.2022 published: Print-Electronic CommentIn: Pharmacol Res. 2022 Feb;176:106054. - PMID 34979234 Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.phrs.2020.105182 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM314634827 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM314634827 | ||
| 003 | DE-627 | ||
| 005 | 20231225153143.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.phrs.2020.105182 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1048.xml |
| 035 | |a (DE-627)NLM314634827 | ||
| 035 | |a (NLM)32890740 | ||
| 035 | |a (PII)S1043-6618(20)31490-0 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Tang, Xiaoling |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Postmenopausal exogenous hormone therapy and Melanoma risk in women |b A systematic review and time-response meta-analysis |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 13.08.2021 | ||
| 500 | |a Date Revised 22.03.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a CommentIn: Pharmacol Res. 2022 Feb;176:106054. - PMID 34979234 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2020 Elsevier Ltd. All rights reserved. | ||
| 520 | |a A favourable option to management symptoms during menopausal transition is menopausal hormone therapy (MHT) but relation among MHT and risk of melanoma is controversial. This study aims to identify, analyse and present the evidence surrounding post-menopausal exogenous hormone therapy and the risk for melanoma in women. A systematic searches of database was conducted in PubMed/MEDLINE, Scopus, and Cochrane without time, region, and language restrictions from inception to April 2020. The DerSimonian and Laird random-effects model was used to estimate combined risk ratio (RR) and 95% confidence intervals (CI). Subgroup analysis and time-response analysis was conducted based on the formulation of used hormone and length of hormone therapy. Combined results from fourteen studies that containing 19 arms with 1,164,077 participants which 4273 of them had melanoma cancer showed increase risk of melanoma in the hormone-treated versus control group 1.14 (95% CI 1.05-1.24, I2: 21%). The stronger and significant relationship between MHT and risk of melanoma was in participants who used oestrogen formulation (RR 1.32, 95% CI 1.17-1.49, I2 = 0%). Moreover, a significant non-linear time-response relation between MHT and melanoma was also in initial three years of MHT (Coef1 = 0.2423, p1 < 0.01). This study reveals a significant direct relationship between the MHT and risk of melanoma in postmenopausal women | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Meta-Analysis | |
| 650 | 4 | |a Systematic Review | |
| 650 | 4 | |a Hormone therapy | |
| 650 | 4 | |a Melanoma | |
| 650 | 4 | |a Menopause | |
| 700 | 1 | |a Zhang, Hongcan |e verfasserin |4 aut | |
| 700 | 1 | |a Cui, Ying |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Liqin |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Zhu |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Yajing |e verfasserin |4 aut | |
| 700 | 1 | |a Huo, Jinzhi |e verfasserin |4 aut | |
| 700 | 1 | |a Cai, Jinfeng |e verfasserin |4 aut | |
| 700 | 1 | |a Rinaldi, Giulia |e verfasserin |4 aut | |
| 700 | 1 | |a Bhagavathula, Akshaya Srikanth |e verfasserin |4 aut | |
| 700 | 1 | |a Xiaopeng, Ying |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Pharmacological research |d 1992 |g 160(2020) vom: 02. Okt., Seite 105182 |w (DE-627)NLM012597384 |x 1096-1186 |7 nnns |
| 773 | 1 | 8 | |g volume:160 |g year:2020 |g day:02 |g month:10 |g pages:105182 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.phrs.2020.105182 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 160 |j 2020 |b 02 |c 10 |h 105182 | ||